Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

Combination Therapy:
The combination of TALVEY (talquetamab) and TECVAYLI (teclistamab) shows high response rates and durable responses in patients with relapsed or refractory multiple myeloma (RRMM), including those with extramedullary disease (EMD).

Safety Profile:
The safety profile of the combination is consistent with the monotherapies of TALVEY and TECVAYLI, indicating a manageable safety profile.

Clinical Significance:
This combination offers a potentially promising off-the-shelf option for patients with advanced multiple myeloma, particularly those with EMD who have limited treatment options.

Study Details:
The Phase 1b RedirecTT-1 study evaluated the combination of TALVEY and TECVAYLI in patients with RRMM who were triple-class exposed. At data cutoff, 44 patients had been treated with the recommended phase 2 regimen (RP2R).

Efficacy in EMD:
Subgroup analysis of patients with EMD showed meaningful overall response rates (ORR) and duration of response (DOR) for bispecific antibody-based treatment, with an ORR of 61.1% and an 18-month DOR of 81.8%.

Future Research:
Johnson & Johnson continues to research this innovative combination to maximize the potential of their portfolio through innovative combination regimens.